New purified Vero-cell vaccine prevents rabies in patients bitten by rabid animals.
The protective effect of a new, potentially economical tissue-culture rabies vaccine, purified vero-cell rabies vaccine (PVRV), was tested in 106 patients bitten by animals with proven rabies. 0.5 ml PVRV was given intramuscularly on days 0, 3, 7, 14, 28, and 91; 47 patients with severe exposure were also given 20 IU/kg human rabies immune globulin (HRIG). All patients are alive and well after 1 year. Side-effects of treatment were negligible. Rabies neutralising antibody (greater than or equal to 1.6 IU) was demonstrated on day 14 and persisted for 1 year in every case. There was no significant suppression of the antibody response by HRIG. If the untreated mortality is 15%, PVRV is 81% efficient in protecting patients against rabies encephalitis (95% confidence limit). PVRV is likely to replace human diploid-cell strain vaccine as the most widely used tissue-culture rabies vaccine.
Suntharasamai
P
P
Warrell
M J
MJ
Warrell
D A
DA
Viravan
C
C
Looareesuwan
S
S
Supanaranond
W
W
Chanthavanich
P
P
Supapochana
A
A
Tepsumethanon
W
W
Pouradier-Duteil
X
X
D000293:Adolescent; D000328:Adult; D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D001733:Bites and Stings / Q000150:complications*; D002415:Cats; D002648:Child; D002675:Child, Preschool; D002522:Chlorocebus aethiops; D046508:Culture Techniques; D004285:Dogs; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007668:Kidney; D008297:Male; D008875:Middle Aged; D011818:Rabies / Q000517:prevention & control* / Q000635:transmission; D011819:Rabies Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D011820:Rabies virus / Q000276:immunology; D014611:Vaccination
D000914:Antibodies, Viral; D011819:Rabies Vaccines